GGrantIndex
← Leaderboards

Tejvir S Khurana

University Of Pennsylvania

$7,406,200
Attributed
$8,441,535
Total exposure
9
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $959.8K · FY200523
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$8,441,535 · 9

By mechanism

R01$4,923,490 · 2
R33$1,457,611 · 2
R21$994,125 · 3
R61$575,548 · 1
UG3$490,761 · 1

Top collaborators

Most similar at University Of Pennsylvania

Same institution · by research overlap

Others in their field

Top investigators on “Muscle

Research focus

MuscleBaseResponseMutationAffectPhenotypeGenesDystrophinBiologyCellsToxic EffectMuscle CellsDoseIn VitroBiochemicalNeuromuscular JunctionUtrophinMolecularPlayProteinsHomologous GeneMediatingUntranslated RegionsValidation

Grant awards (25)

Development of Utrophin Site Blocking Oligos (SBOs) to Treat Duchenne Muscular Dystrophy (DMD)$490,761
UG3 · FY2023 · NS · contact PI
HTS to identify compounds that increase NAD+ levels in neurons and muscle cells$373,195
R33 · FY2023 · NS · contact PI
HTS to identify compounds that increase NAD+ levels in neurons and muscle cells$279,416
R33 · FY2022 · NS · contact PI
HTS to identify compounds that increase NAD+ levels in neurons and muscle cells$575,548
R61 · FY2020 · NS · contact PI
Discovery of Post-transcriptional utrophin upregulator small molecules for Duchenne Muscular Dystrophy therapeutics$402,500
R33 · FY2019 · NS · contact PI
Discovery of Post-transcriptional utrophin upregulator small molecules for Duchenne Muscular Dystrophy therapeutics$402,500
R33 · FY2018 · NS · contact PI
Discovery of Post-transcriptional utrophin upregulator small molecules for Duchenne Muscular Dystrophy therapeutics$402,500
R21 · FY2017 · NS · contact PI
Molecular Characterization of Extraocular Muscle (EOM)$412,002
R01 · FY2010 · EY · contact PI
Preclinical Development of a Novel Therapeutic Strategy for LGMD2B$157,500
R21 · FY2010 · NS · contact PI
Molecular Characterization of Extraocular Muscle (EOM)$397,500
R01 · FY2009 · EY · contact PI
Regulation of Utrophin Promoter in Muscle$286,646
R01 · FY2009 · AR · contact PI
Preclinical Development of a Novel Therapeutic Strategy for LGMD2B$275,625
R21 · FY2009 · NS · contact PI
Molecular Characterization of Extraocular Muscle$377,076
R01 · FY2008 · EY · contact PI
Regulation of Utrophin Promoter in Muscle$286,646
R01 · FY2008 · AR · contact PI
Molecular Characterization of Extraocular Muscle$384,771
R01 · FY2007 · EY · contact PI
Regulation of Utrophin Promoter in Muscle$292,496
R01 · FY2007 · AR · contact PI
Molecular Characterization of Extraocular Muscle$386,938
R01 · FY2006 · EY · contact PI
Regulation of Utrophin Promoter in Muscle$301,231
R01 · FY2006 · AR · contact PI
Molecular Characterization of Extraocular Muscle$396,250
R01 · FY2005 · EY
Regulation of Utrophin Promoter in Muscle$335,228
R01 · FY2005 · AR
Extraocular muscle stem cells for DMD therapy$79,250
R21 · FY2005 · AR
Molecular Characterization of Extraocular Muscle$396,250
R01 · FY2004 · EY
Regulation of Utrophin Promoter in Muscle$335,228
R01 · FY2004 · AR
Extraocular muscle stem cells for DMD therapy$79,250
R21 · FY2004 · AR
Regulation of Utrophin Promoter in Muscle$335,228
R01 · FY2003 · AR